Janux posts what it called ‘positive trial data’ for its novel treatment in patients with late-stage prostate cancer.

Dr Avan Armaghani discusses earlier use of ADCs, artificial intelligence for recurrence prediction, and new endocrine therapy ...

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November ...

Immunotherapy-chemotherapy combination of eftilagimod alfa (efti) and paclitaxel led to strong objective response rates and ...

About 10% of adolescents and young adults treated for solid tumors have a metastatic recurrence, with 5-year rates surpassing ...

But the biotech’s newest update has failed to garner the same investor enthusiasm, with the company’s stock nearly halved following the data drop.

New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test ...

The tests have not been approved by federal regulators, but that hasn’t stopped patients from wanting them — and doctors from worrying.

Imvax has shrugged off the failure of its phase 2b brain cancer trial to hit its primary endpoint, reporting evidence of ...

Recently, The Kuni Foundation sponsored a conversation with the Portland Business Journal about the challenges and ...

Anabel Cano believed she was in the clear after receiving no follow-up for a breast cancer screening in 2023 at Seville's ...